Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $219.33 +1.00%
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
OCCI, VIVO, PMCB, More
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
OCCI, VIVO, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $10.26, $2.22 better than the analyst estimate of $8.04. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $3.44 billion.
GUIDANCE:
Biogen sees FY2020 EPS of $34.00-$36.00, versus the consensus of $32.96. Biogen sees FY2020 revenue of $13.8-14.2 billion, versus the consensus of $13.94 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore cuts HPE rating amid 'tougher setup'
- Copart (CPRT) PT Lowered to $36 at Freedom Broker
- A10 Networks adds ex-Goldman Sachs analyst to its board
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
